Sun Pharma raises Rs 1,000 cr via NCDs
Advertisement
New Delhi: Drug major Sun Pharma Industries said it has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis.
"Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has raised, on private placement basis, Rs 1,000 crore by allotment of 10,000 unsecured redeemable non-convertible debentures of a face value of Rs 10,00,000 each," Sun Pharmaceutical Industries said in a BSE filing.
It further said: "NCDs will be listed on BSE Ltd under two series with Series 1 debentures comprising 5,000 debentures amounting to Rs 500 crore with a tenor of 24 months, and Series 2 debentures comprising 5,000 debentures amounting to Rs 500 crore with a tenor of 39 months."
The company did not elaborate on the usage of proceeds.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.